Thalia Therapeutics advances RNA therapy programs

London – Thalia Therapeutics plc (AIM:THAT) has provided an update on its RNA-based therapeutics development programs and announced its forthcoming interim results report. The company's lead program, THAT-001 (miRisten), is in a Phase 1 dose-escalation clinical trial for patients with relapsed or refractory Acute Myeloid Leukemia, with top-line data expected in the first half of 2027. miRisten works to inhibit microRNA-126, which aids leukemia stem cell survival, and targets AML, which affects over 22,000 new U.S. patients each year.

Thalia has also begun preclinical development of THAT-002, a bispecific siRNA cardiovascular program targeting PCSK9 and lipoprotein(a). This research, conducted with WuXi AppTec (Hong Kong) Limited, includes siRNA synthesis and testing in vitro and in vivo. If preclinical results prove successful, they may advance the program into IND-enabling non-human primate studies in early 2027.

Thalia's THAT-003 program, Nuvec, focuses on targeted RNA delivery to the liver via GalNAc, with ex-vivo work currently underway at the University of Strathclyde to verify payload delivery. The company appointed Luke Cairns, an Executive Director, as Chief Financial Officer to oversee finance while collaborating with CEO David Solomon on strategy.

Thalia recently rebranded from N4 Pharma plc and acquired Sanmirna Therapeutics Inc. in July 2026, followed by a £2.75 million fundraising round. The company will host an analyst briefing and investor presentation on September 30, after the release of its interim results. This report was produced with AI support and reviewed by an editor.